Fosfluconazole for Antifungal Prophylaxis in Very Low Birth Weight Infants by Takahashi, Daijiro et al.
Hindawi Publishing Corporation
International Journal of Pediatrics
Volume 2009, Article ID 274768, 3 pages
doi:10.1155/2009/274768
Clinical Study
Fosﬂuconazole for Antifungal Prophylaxis in
VeryLowBirthWeight Infants
DaijiroTakahashi,1,2 Tomohiko Nakamura,2 Reiko Shigematsu,1 Miyu Matsui,1
ShunsukeAraki,1 Kazuyasu Kubo,1 Hiroshi Sato,1 andAkiraShirahata1
1Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
2Division of Neonatology, Nagano Children’s Hospital, Azumino City, Nagano 399-8288, Japan
Correspondence should be addressed to Daijiro Takahashi, daijiro@med.uoeh-u.ac.jp
Received 26 January 2009; Accepted 8 April 2009
Recommended by Praveen Kumar
We conducted a retrospective case series study to evaluate the safety of fosﬂuconazole prophylaxis for preventing invasive fungal
infection in VLBW infants with a central vascular access. Fosﬂuconazole was administered intravenously at a dose of 6mg/kg
everyday during which time a central venous catheter was placed. A total of 23 infants met the criteria for enrollment in our
study. No cases of fungal infection were detected during the central venous catheter placement in the group. None of the infants
had an elevated β-D-glucan, and all of them were still alive at discharge. Regarding the liver and renal function, no statistically
signiﬁcant diﬀerences were observed before and at the end of fosﬂuconazole prophylaxis. The results of this study demonstrate
that fosﬂuconazole prophylaxis in preventing invasive fungal infection was well tolerated by VLBW infants. This is a ﬁrst report to
describe antifungal prophylaxis using fosﬂuconazole for VLBW infants.
Copyright © 2009 Daijiro Takahashi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Very low birth weight (VLBW) infants are at risk for
invasive fungal infection because of their immature immune
system and the invasive supportive care they require [1].
Candida species rapidly colonize the skin and mucous
membranes of about 60 percent of critically ill neonates
during their ﬁrst month in the neonatal intensive care
unit (NICU), and they can progress to an invasive fungal
infection in up to 20% of these infants [2]. Since the
diagnosis and treatment are often delayed, recent research
attention has focused on strategies to prevent such inva-
sive fungal infection. Fluconazole is an antifungal agent
which is eﬃcacious for the treatment of serious systemic
fungal infections. Prophylaxis with ﬂuconazole reduces the
incidence of colonization and invasive candida infection
in neonates weighing less than 1500g at birth [2, 3].
Kicklighter et al. reported that in infants with a birth
weight <1500g, ﬂuconazole prophylaxis reduced the inci-
dence of candidal colonization during the ﬁrst month of
life from 46% to 15%, a statistically signiﬁcant reduction
[4].
F o s ﬂ u c o n a z o l ei sap h o s p h a t ep r o d r u go fﬂ u c o n a z o l e
which is highly soluble (>100mg/ml) compared with ﬂu-
conazole(4mg/ml).Invitro,fosﬂuconazoleisatleast25-fold
lesspotentthanﬂuconazoleagainstsingleisolatesofCandida
species and Cryptococcus neoformans but in vivo has similar
eﬃcacy to ﬂuconazole [5]. These observations are consistent
with eﬃcient conversion of fosﬂuconazole to ﬂuconazole in
vivo.
Consequently, there is a need for a small volume formu-
lation of ﬂuconazole and the volume can be reduced using
fosﬂuconazole. To date, there has been no report describing
systemic antifungal prophylaxis using fosﬂuconazole for
infantstoassesstheeﬀectofthistreatmentmodalityoninva-
sivefungalinfection.Theaimofourstudywastoevaluatethe
safety of fosﬂuconazole prophylaxis in preventing invasive
fungal infection in VLBW infants with a central vascular
access.
2.MaterialandMethods
We conducted a retrospective case series study to evaluate
the safety of fosﬂuconazole prophylaxis in preterm infants.2 International Journal of Pediatrics
Table 1: Characteristics of the patients’ risk factors for invasive fungal infection.
Baseline characteristics (N = 23)
Birth weight-g
Mean (range) 1088 ±299 (615–1466)
Gastational age-wk
Mean (range) 28.8 ±3.3 (24.5–36.5)
Male/Female sex-no. 12/11
Antinatal steroids-no. (%) 13 (57)
Antinatal antibiotics-no. (%) 9 (39)
Rupture of membranes 24 hr
before delivery-no. (%) 4 (17)
Born at study hospital-no. (%) 22 (96)
Vaginal delivery-no. (%) 5 (22)
APGAR score
1 min 5.4 ± 2.0





Mean (range) 10.3 ±7.8 (3–35)
Treatment received-no. (%)
Steroids 6
Ampicillin and Aminoglycosides 19
Cephalosporins 2
Carbapenems 2
Duration of antibiotics therapy-days
Mean (range) 5.8 ± 1.9 (4–12)
Vascular access-no. (%)
Central vein 23 (100)
Umbiliical 1 (4)
Peripheral arterial 8 (35)
∗
± values are means ± SD. ∗∗The APGAR score ranges from 0 to 10, with higher scores indicating better functioning
Table 2: Comparison of the liver aminotransferase and renal function before and at the end of fosﬂuconazole prophylaxis.
At enrollment At the end of the treatment P-value
AST 45.5 ±32.23 5 .9 ±10.6n . s .
ALT 4.3 ±2.31 0 .8 ±17.5n . s .
BUN 10.2 ±59 .5 ±5.3n . s .
Creatinine 0.7 ±0.60 .8 ±0.1n . s .
AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen.
The study subjects consisted of VLBW infants with a central
vascular access admitted to the NICU at the University of
OccupationalandEnvironmentalHealthbetweenSeptember
2006 to August 2007 and who were administered fosﬂucona-
zole for prophylaxis against invasive fungal infection. The
dataontheinfants’demographic,clinicalcharacteristics,and
outcome were retrospectively collected during hospitaliza-
tion and through a careful review of their medical records.
We also evaluated the diﬀerence in the liver function
(levels of serum aspartate aminotransferase (AST), and
alanine aminotransferase (ALT)) and renal function (blood
urea nitrogen and creatinine) before and at the end of the
administration of fosﬂuconazole. In addition, we monitored
the β-D-glucan levels when the central venous access was
removed.
Fosﬂuconazole (Prodif) was administered intravenously
at a dose of 6mg/kg everyday during which time a central
venous catheter was placed. An invasive candida infection
was deﬁned as the isolation of Candida from the peripheral
blood, cerebrospinal ﬂuid, or other normally sterile bodyInternational Journal of Pediatrics 3
ﬂuid with clinical signs suggesting infection. A statistical
analysis was performed using the t-test for nonparametric
variables. A P value <. 05 was considered to indicate sta-
tistical signiﬁcance. Before enrollment to this study, informed
consent was obtained from each infant’s parents or guardian.
This study was carried out under the control of the Ethics
Committee of Medicine and Medical Care, University of
Occupational and Environmental Health.
3. Results
A total of 23 infants met the criteria for enrollment in our
study. None of the newborn infants was suspected of having
a fungal infection at birth. The patients’ demographic and
neonatal characteristics and major risk factors for fungal
infections are listed in Table 1. The mean gestational age was
28.8 weeks and birth weight was 1088g.
No cases of fungal infection were detected during the
central venous catheter placement in the group. None of
the infants had an elevated β-D-glucan, and all of them
were still alive at discharge. Table 2 shows the comparison
of liver aminotransferase levels and the renal function before
and at the end of fosﬂuconazole prophylaxis. No statistically
signiﬁcant diﬀerences were observed, but the ALT tended
to be higher at the end of the treatment. At the time
when the central venous catheter was removed, elevations
in the serum AST and ALT levels of more than twice
the normal range were recorded in 1 neonate. No serious
adverse events or fosﬂuconazole-related toxic eﬀects were
recorded.Drugadministrationwasnotdiscontinuedbecause
of any presumed adverse events, intolerance or potentially
dangerous interactions with other drugs.
4. Discussion
This study was a case series of VLBW infants with a central
venous access treated with fosﬂuconazole who did not demon-
strate any obvious adverse eﬀects on either the transaminase
levels or the renal function at the dosage used.
A low-volume product would allow for the bolus admin-
istration, reducing ﬂuid and sodium load, and it could also
facilitate access to higher doses. The current intravenous
dosage form requires, for example, with ﬂuconazole a
high-volume infusion which is undesirable in critically ill
patients. A smaller, concentrated product would therefore
oﬀer advantages to the patient in clinical use, especially for
VLBW infants.
AnevaluationoftheadverseeﬀectsamongVLBWinfants
is extremely diﬃcult because these patients are usually both
primarily very sick while they also often receive several
diﬀerent drug therapies concomitantly. In addition, many of
the adverse eﬀects of fosﬂuconazole could not be evaluated
in newborns.
Our study demonstrated that an asymptomatic mild
elevation of ALT occurred. Mild and transient increases of
liver enzymes, without clinical implications, have previously
been described in infants receiving ﬂuconazole [3, 4], and
thereforeatransientincreaseinthehepaticaminotransferase
levels may occur similarly when using fosﬂuconazole in
VLBW infants. Regarding the renal function, no obvious
renal toxicity was observed in our study.
The use of antifungal prophylaxis is associated with the
potential risk of selecting resistant organisms. This may
take the form of either a subtle increase in the minimal
inhibitory concentrations of previously sensitive species or
an increased incidence of inherently resistant species. We did
not investigate drug resistance in this study; therefore, we
would like to study this issue in a future study.
Furthermore, this study was a retrospective and obser-
vational study that consisted of only a small number of
participants; therefore, a prospective controlled randomized
clinical trial on the use of fosﬂuconazole for prophylaxis in
VLBW infants is called for in the future.
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